Develops drugs for cancer treatments.
Jun 2026Revenue $147M/yrExpenses $229M/yr
No trendCash runway ≈ 1.0 years from Jun 2026
Figures by year
When will Karyopharm Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $147M and expenses $229M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $146M | $237M | −$90.7M |
| Dec 2024 | $145M | $265M | −$119M |
| Dec 2023 | $146M | $276M | −$130M |
| Dec 2022 | $157M | $299M | −$142M |
| Dec 2021 | $210M | $308M | −$98.3M |
| Dec 2020 | $108M | $280M | −$172M |
| Dec 2019 | $40.9M | $230M | −$189M |
| Dec 2018 | $30.3M | $210M | −$180M |
| Dec 2017 | $1.60M | $132M | −$131M |
| Dec 2016 | $154K | $111M | −$111M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.